Skip to main content
SpringerLink
Log in

Immunotherapy in hepatocellular carcinoma

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver cancers. The prognosis remains poor—the 5‑year overall-survival (OS) is 12–18%, all stages taken together. Systemic therapy has been limited to the use of tyrosine kinase inhibitors for more than a decade. Now immune therapy has also arrived in the field of systemic HCC treatment. Despite initial enthusiasm, the response rate to single agent immune checkpoint blockade (ICB) in HCC patients is approximately 15–20%. The immune tolerance of the liver and cirrhosis-associated immune dysfunction (CAID) may play a role in the immunological tumor escape phenomenon. The two phase 3 trials of pembrolizumab vs. placebo in second-line treatment (KEYNOTE-240) and nivolumab vs. sorafenib in first-line treatment (CheckMate 459) did not reach their primary endpoint of OS benefit. Pleasant news from IMbrave150 were recently published: the combination therapy of atezolizumab and bevacizumab reached significant benefit in overall response rate (ORR) and overall survival (OS) compared to current standard of care (SOC) sorafenib in patients advanced HCC in first-line therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of hepatology. 2018;69(1):182–236. https://doi.org/10.1016/j.jhep.2018.03.019. PubMed PMID: 29628281.

  2. Hilmi M, Vienot A, Rousseau B, Neuzillet C. Immune therapy for liver cancers. Cancers. 2019; https://doi.org/10.3390/cancers12010077.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E86. https://doi.org/10.1002/ijc.29210.

    Article  CAS  PubMed  Google Scholar 

  4. Duan J, Wu Y, Liu J, Zhang J, Fu Z, Feng T, et al. Genetic biomarkers for hepatocellular carcinoma in the era of precision medicine. J Hepatocell Carcinoma. 2019;6:151–66. https://doi.org/10.2147/jhc.s224849.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Hilmi M, Neuzillet C, Calderaro J, Lafdil F, Pawlotsky JM, Rousseau B. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. J Immunother Cancer. 2019;7(1):333. https://doi.org/10.1186/s40425-019-0824-5.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol. 2013;14(10):996–1006. https://doi.org/10.1038/ni.2691.

    Article  CAS  PubMed  Google Scholar 

  7. Noor MT, Manoria P. Immune dysfunction in cirrhosis. JCTH. 2017;5(1):50–8. https://doi.org/10.14218/jcth.2016.00056.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Tai D, Choo SP, Chew V. Rationale of immunotherapy in hepatocellular carcinoma and its potential Biomarkers. Cancers. 2019; https://doi.org/10.3390/cancers11121926.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The immune landscape of cancer. Immunity. 2018;48(4):812–830e14. https://doi.org/10.1016/j.immuni.2018.03.023.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7. https://doi.org/10.1038/nmeth.3337.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169(7):1327–1341e23. https://doi.org/10.1016/j.cell.2017.05.046.

    Article  CAS  Google Scholar 

  12. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–52. https://doi.org/10.1016/s1470-2045(18)30351-6.

    Article  PubMed  Google Scholar 

  13. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502. https://doi.org/10.1016/s0140-6736(17)31046-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Yau T, Park JW, Finn RS, Cheng A‑L, Mathurin P, Edeline J, et al. LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019; https://doi.org/10.1093/annonc/mdz394.029.

    Article  Google Scholar 

  15. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as second-line therapy in patients with advanced Hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2019; https://doi.org/10.1200/jco.19.01307.

    Article  PubMed  Google Scholar 

  16. Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, Garralda E, Barrera P, et al. A clinical trial of CTLA‑4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81–8. https://doi.org/10.1016/j.jhep.2013.02.022.

    Article  CAS  PubMed  Google Scholar 

  17. Kelley RK, Abou-Alfa GK, Bendell JC, Kim T‑Y, Borad MJ, Yong W‑P, et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. J Clin Oncol. 2017;35(15_suppl):4073. https://doi.org/10.1200/JCO.2017.35.15_suppl.4073.

    Article  Google Scholar 

  18. Yau T, Kang Y‑K, Kim T‑Y, El-Khoueiry AB, Santoro A, Sangro B, et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from checkmate 040. J Clin Oncol. 2019;37(15_suppl):4012. https://doi.org/10.1200/JCO.2019.37.15_suppl.4012.

    Article  Google Scholar 

  19. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016; https://doi.org/10.1038/nrdp.2016.18.

    Article  PubMed  Google Scholar 

  20. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70(15):6171–80. https://doi.org/10.1158/0008-5472.can-10-0153.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Manzoni M, Rovati B, Ronzoni M, Loupakis F, Mariucci S, Ricci V, et al. Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. Oncology. 2010;79(3–4):187–96. https://doi.org/10.1159/000320609.

    Article  CAS  PubMed  Google Scholar 

  22. American Association for Cancer Research. Combo poised to become standard in HCC. Cancer Discov. 2020; https://doi.org/10.1158/2159-8290.cd-nb2019-145.

    Article  Google Scholar 

  23. Kudo M, Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kurosaki M, et al. First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100). J Clin Oncol. 2019;37(15_suppl):4072. https://doi.org/10.1200/JCO.2019.37.15_suppl.4072.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Hepatology, Ordensklinikum Barmherzige Schwestern Linz, Seilerstätte 4, 4020, Linz, Austria

    Stephanie Hametner-Schreil

Authors
  1. Stephanie Hametner-Schreil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephanie Hametner-Schreil.

Ethics declarations

Conflict of interest

S. Hametner-Schreil declares that she has no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hametner-Schreil, S. Immunotherapy in hepatocellular carcinoma. memo 13, 218–222 (2020). https://doi.org/10.1007/s12254-020-00592-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-020-00592-2

Keywords

Search

Navigation